Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02JCM
|
|||
| Former ID |
DIB020463
|
|||
| Drug Name |
N(6)-cyclohexyladenosine
|
|||
| Synonyms |
N6-Cyclohexyladenosine; 36396-99-3; (2R,3R,4S,5R)-2-(6-(Cyclohexylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; N(6)-Cyclohexyladenosine; C16H23N5O4; Adenosine, N-cyclohexyl-; CHEMBL45891; (2R,3R,4S,5R)-2-[6-(cyclohexylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; n-cyclohexyladenosine; N6 -cyclohexyladenosine; N-6-cyclohexyladenosine; N6-Cyclohexylado (CHA); n6-cyclohexyl[3h]adenosine; Lopac0_000331; GTPL423; SCHEMBL145856; SZBULDQSDUXAPJ-XNIJJKJLSA-N; MolPort-027-835-536; HMS3261C03; ZINC4217017
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C16H23N5O4
|
|||
| Canonical SMILES |
C1CCC(CC1)NC2=C3C(=NC=N2)N(C=N3)C4C(C(C(O4)CO)O)O
|
|||
| InChI |
1S/C16H23N5O4/c22-6-10-12(23)13(24)16(25-10)21-8-19-11-14(17-7-18-15(11)21)20-9-4-2-1-3-5-9/h7-10,12-13,16,22-24H,1-6H2,(H,17,18,20)/t10-,12-,13-,16-/m1/s1
|
|||
| InChIKey |
SZBULDQSDUXAPJ-XNIJJKJLSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14802819, 17404894, 24139429, 26753545, 44939362, 47574445, 47574446, 47574447, 47721688, 47796119, 47870803, 48095612, 50106092, 50106093, 53777437, 79854249, 90341655, 92303773, 103228861, 103922563, 103959360, 121361167, 124749627, 129309435, 134224717, 135650675, 140033717, 143178625, 162090737, 163410110, 163564285, 163848500, 172855788, 189053184, 223558168, 224442731, 226512189, 249846057, 252035498, 252212978, 252484514
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 423). | |||
| REF 2 | Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. Pharmacology. 1993;46(2):91-100. | |||
| REF 3 | Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol. 1980 Jun;58(6):673-91. | |||
| REF 4 | Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol. 1996 May 1;156(9):3435-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.